Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | CKS1B | P61024 | 1/20 | 0.40 |
| ▸ | SKP1 | P63208 | 1/20 | 0.40 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29475511 | 1.00 | JAK2 (0.46) | JAK2JAK1OPRD1OPRK1SYK | |
| SCHEMBL27196781 | 0.86 | SYK (0.45) | OPRD1OPRK1SYKGPR119RORC | |
| SCHEMBL29980884 | 0.85 | OPRD1 (0.42) | OPRD1OPRK1SYKPOLBGPR119 | |
| SCHEMBL12489219 | 0.85 | OPRD1 (0.42) | OPRD1OPRK1SYKPOLBGPR119 | |
| SCHEMBL12453384 | 0.85 | NAMPT (0.45) | JAK2JAK1OPRD1OPRK1SYK | |
| SCHEMBL31314534 | 0.85 | NAMPT (0.45) | JAK2JAK1OPRD1OPRK1SYK | |
| SCHEMBL19491057 | 0.85 | OPRD1 (0.42) | OPRD1OPRK1SYKPOLBGPR119 | |
| SCHEMBL2264830 | 0.85 | DRD2 (0.47) | OPRD1OPRK1SYKPOLBTSHR | |
| SCHEMBL3024794 | 0.84 | GPR119 (0.53) | OPRD1OPRK1SYKPOLBGPR119 | |
| SCHEMBL3266179 | 0.83 | RORC (0.51) | HDAC1HDAC2RORCDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107759563-B | Preparation method of 4- (6-substituted aminopyridine-3-yl) piperidine-1-tert-butyl formate | 上海再启生物技术有限公司 | 2020-06-02 | — | — | CN | claimed |
| US-20240043395-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. | 2024-02-08 | — | — | US | disclosed |
| EP-4217342-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | Neuropore Therapies, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116507607-A | Compounds and compositions as modulators of TLR signaling | 神经孔疗法股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2022067114-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| CN-107759563-B | Preparation method of 4- (6-substituted aminopyridine-3-yl) piperidine-1-tert-butyl formate | 上海再启生物技术有限公司 | 2020-06-02 | — | — | CN | disclosed |
| US-20100324049-A1 | DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR | MSD K.K. (JP) | 2010-12-23 | — | — | US | disclosed |
| US-7727998-B2 | Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20060106046-A1 | Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient | MSD K.K. (JP) | 2006-05-18 | — | — | US | disclosed |
| EP-1595867-A1 | MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS CONTAINING PIPERIDINE DERIVATIVES AS THE ACTIVE INGREDIENT | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043395-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | TLR3, TLR6, TLR4 | JAK2 454/4885JAK1 1190/4885OPRD1 1906/4885 |
| US-20100324049-A1 | DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR | MC1R, MCHR1, MCHR2 | JAK2 249/4885JAK1 308/4885OPRD1 74/4885 |
| US-20060106046-A1 | Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient | MCHR1, MC1R, PRLHR | JAK2 128/4885JAK1 923/4885OPRD1 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.